

1 **RNase L amplifies Interferon signaling by inducing PKR-mediated antiviral stress**  
2 **granules**

3 Praveen Manivannan<sup>1</sup>, Mohammad Adnan Siddiqui<sup>2</sup> and Krishnamurthy Malathi<sup>1#</sup>

4 <sup>1</sup>Department of Biological Sciences, University of Toledo, 2801 West Bancroft Street,  
5 Toledo, OH 43606, USA

6 <sup>2</sup>Department of Medicine, Division of Infectious Diseases, Columbia University Medical  
7 Center, New York, NY 10032, USA

8 #Correspondence: [Malathi.Krishnamurthy@utoledo.edu](mailto:Malathi.Krishnamurthy@utoledo.edu)

9

10

11 Running title: RNase L induces antiviral stress granules.

12 Key words: RNase L, Stress Granules, interferon, double-stranded RNA, PKR, Rig-I

13

14

15

16

17

18

19

20 **ABSTRACT**

21 Virus infection leads to activation of the interferon-induced endoribonuclease, RNase L,  
22 which results in degradation of viral and cellular RNAs. Both cellular and viral RNA  
23 cleavage products of RNase L bind pattern recognition receptors (PRR) like Retinoic acid-  
24 inducible I (Rig-I) and or melanoma differentiation-associated protein 5 (MDA5) to further  
25 amplify interferon (IFN) production and antiviral response. Although much is known about  
26 the mechanics of ligand binding and PRR activation, how the cells coordinate RNA  
27 sensing to signaling response and interferon production remains unclear. We show that  
28 RNA cleavage products of RNase L activity induce formation of antiviral stress granule  
29 (avSG) by regulating activation of double-stranded RNA (dsRNA)-dependent protein  
30 kinase R (PKR), and recruit antiviral proteins Rig-I, PKR, OAS and RNase L to avSG.  
31 Biochemical analysis of purified avSG showed interaction of key stress granule protein,  
32 G3BP1, with only PKR and Rig-I and not with OAS or RNase L. AvSG assembly during  
33 RNase L activation is required for IRF3-mediated IFN production and not IFN signaling or  
34 proinflammatory cytokine induction. Consequently, cells lacking avSG formation or  
35 RNase L signaling produced less IFN and showed higher susceptibility during Sendai  
36 virus infection demonstrating the importance of avSG in RNase L-mediated host defense.  
37 During viral infection, we propose a role for RNase L-cleaved RNAs in inducing avSG  
38 containing antiviral proteins to provide a platform for efficient interaction of RNA ligands  
39 with pattern recognition receptors to enhance IFN production to effectively mount antiviral  
40 response.

41

42 Word count: 238

43 **IMPORTANCE**

44 Double-stranded RNAs produced during viral infections serve as pathogen associated  
45 molecular patterns (PAMPs) and bind pattern recognition receptors to stimulate IFN  
46 production. RNase L is an IFN-regulated endoribonuclease that is activated in virus-  
47 infected cells and cleaves single-stranded viral and cellular RNAs. The RNase L-cleaved  
48 dsRNAs signal to Rig-like helicases to amplify IFN production. This study identifies a  
49 novel role of antiviral stress granules induced by RNase L as an antiviral signaling hub to  
50 coordinate the RNA ligands with cognate receptors to mount effective host response  
51 during viral infections.

52

53

54 Word count: 88

55

56

57

58

59

60

61

62

## 63 INTRODUCTION

64 Viral invasion and replication are detected in host cells by Pathogen Recognition  
65 Receptors (PRRs) triggering signaling pathways that result in production of type 1  
66 interferon (IFN) (1-3). IFN produced by virus-infected cells acts in autocrine and paracrine  
67 ways by binding to cell surface receptors (IFNAR) to induce expression of antiviral IFN-  
68 stimulated genes (ISGs) including Rig-I, MDA5, 2'-5'-oligoadenylate synthetase (OAS),  
69 RNase L, dsRNA-dependent protein kinase R (PKR), Interferon Induced proteins with  
70 Tetratricopeptide repeats (IFIT) to perpetuate antiviral signaling(3, 4). Recognition of viral  
71 nucleic acids that serve as Pattern Associated Molecular Patterns (PAMPs) is  
72 accomplished by PRRs like the endosomal Toll-like Receptors (TLR3, 7/8, 9), cytosolic  
73 Rig-I like receptors (RLRs, Rig-I, MDA5), DExD/H-box helicases (DDX1, DDX21, DHX33,  
74 and DHX36), protein kinase R (PKR), 2',5'-oligoadenylate synthetases (OAS), or cytosolic  
75 DNA sensors (DAI, STING, cGAS) by virtue of their compartment-specific distribution in  
76 cells and modification on the RNAs or DNA (5-12). RLRs detect cytoplasmic viral RNAs  
77 and discriminate self from viral RNAs by recognizing double-stranded structures and 5'-  
78 triphosphate that are lacking on self RNAs(13). Rig-I and MDA5 contain an RNA helicase  
79 domain for binding RNA and a caspase recruitment domain (CARD) for downstream  
80 signaling (14). In case of Rig-I, RNA binding allows K63 ubiquitination of the CARD  
81 domain by TRIM25 and ATPase activity induces conformational change and  
82 oligomerization (15). In contrast, Rig-I undergoes degradation after conjugation to E3  
83 ubiquitin ligase RNF125 (16). The Rig-I CARD domain interacts with the CARD-like  
84 domain of the IFN- $\beta$  promoter stimulator-1 (IPS-1/MAVS/VISA/Cardif) at the outer  
85 mitochondrial membrane via CARD-CARD interaction, which further activates TRAF3

86 and TBK1(17-20). TBK1 phosphorylates IRF3 that translocate to the nucleus to induce  
87 IFN production (21, 22).

88 Double-stranded RNA-dependent protein kinase R (PKR) is activated by binding dsRNA  
89 ligands and participates in integrated stress response during viral infections (23). RNA  
90 binding induces dimerization and autophosphorylation resulting in activation and  
91 phosphorylation of eIF2 $\alpha$  (eukaryotic initiation factor 2 alpha subunit)(24). Phosphorylated  
92 eIF2 $\alpha$  represses translation and causes aggregation of stalled translation preinitiation  
93 complexes containing mRNAs, initiation factors, small ribosomal subunits, RNA-binding  
94 proteins together with the Ras-GAP SH3 domain binding protein (G3BP) and T-cell  
95 restricted intracellular antigen 1(TIA 1) into stress granules (SG)(25).

96 SGs are nonmembranous RNA-protein complexes that are formed in the cytoplasm in  
97 response to diverse stress signals including viral infections (26). Complex RNA-protein  
98 interactions in the SG establish a liquid-liquid phase separation from the rest of the  
99 cytoplasm, facilitating recruitment of multiple proteins into a dynamic compartment (27).  
100 Depending on the nature of the stress signal protein kinases such as PKR (protein kinase  
101 R), GCN2 (general control nonderepressible 2), HRI (heme-regulated inhibitor) or PERK  
102 (PKR-like ER kinase) phosphorylate translation initiation factor, eIF2 $\alpha$ , to inhibit  
103 translation which in turn promotes SG formation (28-30). SG composition and proteins  
104 recruited vary depending on the type of stimulus and cell type but G3BP1 is required for  
105 nucleation in all contexts. SG were considered general triage sites for mRNA turnover,  
106 however, recent studies show selective exclusion from SGs of some transcripts needed  
107 to overcome stress (31-33). Compared to these canonical SGs formed under stress  
108 conditions, antiviral SGs form during viral infections and have been proposed to play a

109 role in antiviral signaling (34) by recruiting antiviral proteins including PKR, Rig-I, MDA5,  
110 OAS, RNase L, Trim5, ADAR1, ZAP, cGAS and RNA helicases like DHX36, DDX3 and  
111 DDX6 (35-38). Assembly of avSG was required for signaling to produce IFN during NDV,  
112 IAV and SINV infections. During IAV infection, SG are induced and both IAV viral RNA  
113 and Rig-I are sequestered in SG, thereby providing a platform for sensing of viral RNA by  
114 Rig-I (35, 39). In addition, antiviral proteins like PKR, OAS, RNase L, LGP2 and MDA5  
115 were also shown to coalesce in avSGs (35, 36, 40, 41). Several viruses counteract SG  
116 formation by targeting SG proteins through G3BP1 cleavage or by inhibiting upstream  
117 eIF2 $\alpha$  pathway to support viral replication suggesting an important role of SG in viral  
118 pathogenesis (42, 43).

119 In most vertebrates, viruses induce an RNA degradation process that is regulated  
120 through the action of the ubiquitous cellular endoribonuclease, RNase L. Type I IFN  
121 produced during viral infections transcriptionally induces OAS proteins that are activated  
122 by binding dsRNA to produce a unique 2', 5'-oligoadenylate, 2-5A ((p $x$ 5'A(2'p5'A) $n$ ;  $x =$   
123 1-3;  $n \geq 2$ ), produced from cellular ATP. The only established function of 2-5A is activation  
124 of RNase L. RNase L is expressed as an inactive monomer and binding 2-5A promotes  
125 dimerization and conversion to an active enzyme that targets single-stranded viral and  
126 cellular RNA after UU/UA nucleotide sequences resulting in dsRNA cleavage products  
127 with 5'-hydroxyl and 2',3'-cyclic phosphate ends(10, 44, 45). While activity of RNase L on  
128 viral genome or mRNA directly eliminates viruses, the dsRNA cleavage products signal  
129 through Rig-I/MDA5/ MAVS (IPS-1) and IRF3 to induce IFN production (46). RNase L-  
130 cleaved RNAs also induce NLRP3 inflammasome and promote switch from RNase L-  
131 induced autophagy to apoptosis by promoting cleavage of autophagy protein, Beclin-1

132 (47, 48). The role of RNase L in generating dsRNA with IFN-inducing abilities and the  
133 multiple overlapping signaling pathways activated by avSG during viral infections  
134 prompted us to explore the role of RNase L-cleaved RNAs in inducing avSG formation as  
135 a platform for antiviral signaling. Our results show that direct activation of RNase L with  
136 2-5A or treatment with RNase L-cleaved RNAs induced avSG formation by activating  
137 PKR and phosphorylation of eIF2 $\alpha$ . Characterization of purified avSG showed the  
138 interaction of G3BP1 in avSG with only PKR and Rig-I, but not OAS or RNase L. AvSG  
139 assembly was required for IRF3-mediated IFN production, but not IFN signaling or  
140 proinflammatory cytokine induction and affected viral pathogenesis. These studies  
141 demonstrate avSG assembly induced by RNase L as an antiviral signaling hub to  
142 coordinate RNA ligands with PRRs to mount effective antiviral response.

## 143 **RESULTS**

### 144 **RNase L activation induces formation of antiviral stress granules containing** 145 **antiviral proteins**

146 Viral infection or dsRNA causes aggregation of Rig-I, PKR, OAS and RNase L in antiviral  
147 stress granules (avSG) for production of type I IFN by providing a platform for integrating  
148 RNA ligands with antiviral proteins. The role of dsRNA by-products of RNase L enzyme  
149 activity in regulating type I IFN production prompted us to explore avSG formation during  
150 RNase L activation. Transfection of HT1080 fibrosarcoma cells with 2-5A, a highly specific  
151 ligand and activator of RNase L, resulted in a characteristic rRNA cleavage pattern (Fig.  
152 1A) and localization of key stress granule protein, G3BP1, in distinct stress granules  
153 compared to diffuse distribution in mock treated cells (Fig. 1B). To determine if these 2-  
154 5A-induced stress granules are antiviral stress granules, we performed

155 immunofluorescence assays for RNA-binding antiviral proteins Rig-I, PKR, OAS and  
156 RNase L with G3BP1. We observed significant co-localization of these antiviral proteins  
157 on RNase L activation in avSGs (Fig. 1B). Following 2-5A transfection, compared to mock  
158 treated cells, 32% cells formed stress granules (Fig. 1C). To demonstrate that avSGs  
159 were formed in response to RNase L activation, we generated CRISPR-mediated  
160 knockout of RNase L in HT1080 cells (49) and observed no avSG formation with 2-5A  
161 transfection (Fig.1D). AvSG formation was restored in these cells only by expression of  
162 Flag-WT RNase L and not Flag-RNase L R667A mutant which lacked enzyme activity  
163 (Fig. 1D) (Ref). These results suggest that direct activation of RNase L by 2-5A induces  
164 formation of avSG and Rig-I, PKR, OAS and RNase L are recruited to these avSG.

165 Antiviral stress granules are distinct from canonical stress granules and characterized by  
166 the presence of antiviral RNA-binding proteins, RNA helicases and RNA ligands that form  
167 during viral infection (50). To demonstrate the distinct nature of avSG, we treated HT1080  
168 cells with H<sub>2</sub>O<sub>2</sub> to induce oxidative stress that promotes formation of stress granules.  
169 While SGs formed in 30% of H<sub>2</sub>O<sub>2</sub>-treated cells as shown by G3BP1 puncta, there was  
170 no co-localization of antiviral proteins Rig-I, PKR, OAS or RNase L in these granules (Fig.  
171 1E, F). These results support observations made by others and demonstrate that avSGs  
172 are unique and distinct from canonical SGs that form in response to diverse stress stimuli  
173 including oxidative stress (35, 36).

#### 174 **RNase L-cleaved small RNAs activate PKR to induce avSG**

175 The RNA cleavage products of RNase L are predominantly small dsRNA that signal via  
176 Rig-I and/or MDA5 and MAVS (IPS-1) to amplify IFN signaling (46). The stress-induced  
177 eIF2 $\alpha$  kinases like PKR, PERK, GCN2 and HRI phosphorylate eIF2 $\alpha$  resulting in



178 formation of SG. PKR is activated by binding dsRNA so we tested the hypothesis that  
179 RNase L-cleaved small RNAs activate PKR and promote the formation of avSG by  
180 phosphorylation of eIF2 $\alpha$ . RNase L-cleaved small RNAs or control small RNAs were  
181 purified as previously described (46) and phosphorylation of PKR was monitored following  
182 transfection at indicated times in HT1080 cells. RNase L-cleaved small RNAs induced  
183 autophosphorylation of PKR 4h post transfection that increased over time compared to  
184 control small RNAs (Fig. 2A). PKR phosphorylation correlated with eIF2 $\alpha$  phosphorylation  
185 only in cells treated with RNase L-cleaved small RNAs but not control small RNAs (Fig.  
186 2B). No phosphorylation of eIF2 $\alpha$  by RNase L-cleaved RNAs was observed in cells  
187 lacking PKR generated by CRISPR-Cas9 technology (Fig. 2B, C). Taken together, these  
188 results indicate that RNase L-cleaved small RNAs activate PKR to phosphorylate eIF2 $\alpha$ .  
189 To determine if PKR-induced phosphorylation of eIF2 $\alpha$  translates into avSG formation,  
190 we analyzed avSG formation in PKR KO cells by immunofluorescence analysis and  
191 compared with G3BP1 KO, RNase L KO, Rig-I KO and PKR/Rig-I double KO (DKO) cells  
192 and calculated the frequency of avSG (Fig. 2D, E). As expected, about 35% of 2-5A  
193 transfected WT and Rig-I KO cells formed avSG, and cells lacking RNase L, PKR or  
194 PKR/Rig-I DKO did not form avSG. G3BP1 is necessary to form avSG in response to  
195 RNase L activation as cells lacking G3BP1 did not induce avSG. When the RNase L-  
196 cleaved RNAs were introduced in cells, in addition to WT (38%) and Rig-I KO cells (39%),  
197 cells lacking RNase L also formed avSG (34%) suggesting a role for the RNase L cleaved  
198 RNAs products in promoting avSG formation. Control small RNAs did not induce avSG in  
199 any of the cells. Previous studies show the presence of 5'OH and 2',3-cyclic phosphoryl  
200 on RNase L-cleaved products contribute to IFN production as removal of the 2',3-cyclic

201 phosphates by treatment with calf intestinal phosphatase reduced IFN production (46).  
202 Removal of terminal 2',3-cyclic phosphoryl on RNase L-cleaved RNAs significantly  
203 reduced avSG formation (Fig. 2D, E). In contrast, formation of canonical SGs in response  
204 to oxidative stress by H<sub>2</sub>O<sub>2</sub> is not impacted in cells lacking PKR, RNase L, Rig-I or both  
205 PKR/Rig-I (Fig. 2F). Finally, 2-5A transfected cells stained with monoclonal antibody  
206 against dsRNA showed co-localization with G3BP1 in avSGs by immunofluorescence  
207 assays (Fig. 2G). These findings demonstrate that RNase L enzyme activity produces  
208 small dsRNAs that activate PKR to phosphorylate eIF2 $\alpha$  and induce formation of avSGs.

### 209 **Co-localization of PKR, Rig-I, OAS and RNase L in avSG on RNase L activation**

210 Studies have reported that avSG provide a platform to coordinate viral sensing and IFN  
211 production by recruiting antiviral proteins and RNA ligands. We characterized avSGs  
212 formed during RNase L activation by adapting a method recently used to purify SG core  
213 from GFP-G3BP1 expressing cells with some changes(51). Expression of GFP-G3BP1  
214 induced SG independent of stimuli, so we used antibodies towards endogenous G3BP1  
215 to immunoprecipitate and test interaction of antiviral proteins from purified avSG core  
216 following 2-5A treatment in WT, G3BP1 KO and RNase L KO cells (Fig. 3A, B). As PKR,  
217 Rig-I, OAS and RNase L co-localized with G3BP1 on 2-5A treatment, we examined if they  
218 purified with avSG core and tested physical interaction in the avSG core by co-  
219 immunoprecipitation. Cells were mock transfected or transfected with 2-5A and avSG  
220 core were purified by multiple rounds of centrifugation as described in methods. The cell  
221 pellet and core were analyzed for expression of PKR, Rig-I, OAS and RNase L and their  
222 interaction with G3BP1 was monitored in immune complexes by immunoblotting.  
223 Interaction of PKR and Rig-I with G3BP1 in the avSG core was seen only after 2-5A

224 transfection, however, OAS and RNase L were present in the avSG core but did not  
225 interact with G3BP1. MAVS (IPS-1), a mitochondrial adaptor protein required for IFN  
226 production and RNase L-mediated IFN induction was not present in avSG core (Fig. 3B).  
227 As expected, cells lacking G3BP1 or RNase L did not assemble avSG core in response  
228 to 2-5A. These results are consistent with avSG co-localization and interaction of G3BP1  
229 with PKR and Rig-I during IAV $\Delta$ NS1 and NDV infection (35, 36). To further characterize  
230 the avSG formation by RNase L-cleaved small RNAs, avSG core was purified from  
231 transfected cells and compared to control small RNAs (Fig. 3C). Consistent with avSG  
232 formation, RNase L-cleaved small RNAs promoted interaction of G3BP1 with PKR and  
233 Rig-I as observed with 2-5A, however, both OAS and RNase L while present in the core  
234 do not interact with G3BP1. As expected, when RNase L-cleaved RNAs were introduced  
235 into RNase L KO cells, they induced formation of avSG and both PKR and Rig-I interacted  
236 with G3BP1 in avSG core and cells lacking G3BP1 did not form avSG (Fig. 3C). We  
237 compared these avSG to the canonical SG formed in response to oxidative stress by  
238 treating cells with H<sub>2</sub>O<sub>2</sub> and analyzed the SG core for the presence of antiviral proteins.  
239 Consistent with our data in Fig. 2, WT cells formed SG core and none of the antiviral  
240 proteins were interacting or present in the SG and cells lacking G3BP1 did not form SG  
241 core (Fig. 3D). These results allowed us to analyze the biochemical features of avSG and  
242 reveal that unlike antiviral proteins OAS and RNase L that are components of avSG and  
243 do not interact with the key proteins like G3BP1, PKR and Rig-I interact with G3BP1 and  
244 presumably form the scaffold and core of SG. These results also raise the possibility of  
245 existence of different types of complexes in the SG cores that coalesce to form a mature  
246 stress granule.

247 **avSG assembly by RNase L is required for IRF3-mediated interferon induction but**  
248 **not for interferon signaling**

249 Activation of RNase L by 2-5A produces dsRNA intermediates that signal through Rig-I  
250 and or MDA5 via mitochondrial adaptor, MAVS (IPS-1) by activating IRF3 that  
251 translocates to the nucleus to enhance IFN- $\beta$  production (46). Various studies have  
252 shown that G3BP1 binds to Rig-I to regulate IFN- $\beta$  production in response to viral RNA  
253 and synthetic dsRNA, polyI:C (39, 52, 53). To examine whether G3BP1 participates in  
254 RNase L-mediated IFN- $\beta$  production, we monitored IFN- $\beta$  promoter activation in WT and  
255 G3BP1 KO cells by directly activating RNase L with 2-5A or introducing RNase L-cleaved  
256 small RNAs and compared to control small RNAs. In cells lacking G3BP1, IFN- $\beta$  promoter  
257 activation was significantly reduced in response to both 2-5A and RNase L-cleaved small  
258 RNAs (Fig. 4A). Consequently, activation of promoters of interferon-stimulated genes  
259 (ISGs) like ISG15 and ISG56/IFIT1 that are induced transcriptionally by IFN was also  
260 reduced. Consistent with the above observations, mRNA levels of IFN- $\beta$ , ISG15 and  
261 ISG56/IFIT1 were reduced in cells lacking G3BP1 in response to RNase L activation (Fig.  
262 4B). Overexpression of MAVS (IPS-1) activates signaling pathways downstream of Rig-  
263 like receptors resulting in phosphorylation and nuclear translocation of IRF3 to promote  
264 IFN- $\beta$  production (18). In the absence of G3BP1, no difference in IFN- $\beta$  promoter  
265 activation or IFN- $\beta$  mRNA levels was observed in MAVS overexpressing cells suggesting  
266 avSG functions upstream of MAVS (IPS-1) (Fig. 4C). This is consistent with the absence  
267 of MAVS (IPS-1) in avSG core with RNase L activation (Fig. 3B). Furthermore,  
268 overexpression of MAVS (IPS-1) did not induce SG formation (Fig.4C). To further  
269 investigate the requirement of avSG in IRF3 activation, we monitored nuclear

270 translocation of GFP-IRF3 in response to 2-5A for indicated times in WT and G3BP1 KO  
271 cells by confocal microscopy. Loss of G3BP1 diminished GFP-IRF3 nuclear translocation  
272 3-fold compared to WT cells (29% vs 60%) (Fig. 4D). We used a luciferase-based IRF3  
273 transactivation assay to measure phosphorylation-dependent IRF3 activity. The assay  
274 uses Gal4 DNA-binding domain and IRF3 transactivation domain driving luciferase  
275 expression under Gal4 promoter when IRF3 is phosphorylated (21). In G3BP1 KO cells,  
276 2-5A induction of IRF3 transactivation was 44% that of WT cells expressing G3BP1 (Fig.  
277 4E). As expected, overexpression of MAVS (IPS-1) resulted in similar levels of IRF3  
278 transactivation independent of G3BP1 expression (Fig. 4F). The effect of G3BP1 on  
279 RNase L-mediated IFN- $\beta$  production was apparent from reduced phosphorylation of PKR,  
280 IRF3 and STAT1 following 2-5A treatment in lysates of cells lacking G3BP1 or RNase L  
281 compared to strong activation in control WT cells (Fig. 4G). While activation of dsRNA  
282 signaling pathway specifically promotes avSG assembly to induce IFN, H<sub>2</sub>O<sub>2</sub> treatment  
283 forms SGs and does not activate PKR, IRF3 or produce IFN (Fig. 4H). Together, our data  
284 suggest that G3BP1 is essential for RNase L-mediated IFN induction by promoting avSG  
285 assembly containing antiviral proteins and activating IRF3.

286 IFN secreted by virus infected cells binds to type I IFN receptor on cell surface and  
287 activates JAK-STAT signaling pathway leading to transcriptional induction of several  
288 interferon stimulated genes (ISGs) with roles in viral clearance mechanisms. Our results  
289 show the requirement of avSG in producing IFN in response to RNase L activation,  
290 however, the role in IFN signaling is not clear. To examine this, we treated cells with type  
291 I IFN and monitored transcriptional induction of ISG15 and ISG56 using real-time PCR  
292 and promoter-driven luciferase reporter assays. In the absence of G3BP1, no significant

293 differences in mRNA levels of both ISG15 and ISG56 or promoter-driven luciferase  
294 activity were observed on IFN treatment (Fig. 5A, B). Exposure of WT, G3BP1 KO or  
295 RNase L KO cells to type I IFN resulted in similar levels of phosphorylation of STAT1  
296 accompanied by comparable levels of induction of ISGs like OAS2, OAS3, ISG56 in cell  
297 lysates on immunoblots analysis (Fig. 5C). Phosphorylated STAT1 translocates to the  
298 nucleus to induce transcription of genes regulated by IFN-stimulated response elements  
299 (ISRE) (3). No significant difference in phospho-STAT1 accumulation in the nucleus was  
300 observed with IFN treatment in cells lacking G3BP1 or RNase L compared to control WT  
301 cells (Fig. 5C, D). Taken together, these results indicate that avSG assembly that requires  
302 G3BP1 protein, is required for IFN production in response to RNase L activation.  
303 However, following IFN production, G3BP1 is dispensable for activation of JAK-STAT  
304 signaling pathway to transcriptionally induce ISGs.

### 305 **Induction of proinflammatory cytokines by RNase L is independent of antiviral** 306 **stress granule assembly**

307 Activation of RNase L or treatment with RNase L-cleaved RNAs induces inflammatory  
308 signaling pathways and proinflammatory cytokines (47, 54). We have demonstrated that  
309 avSG is required for RNase L-mediated IFN production, however, the requirement of  
310 avSG in inducing proinflammatory cytokines during RNase L activation is not known. To  
311 determine the effect of avSG on cytokine induction during RNase L activation, we  
312 monitored CCL5 (RANTES), IL-8 or IP-10 promoter activation using luciferase reporter  
313 constructs in WT and G3BP1 KO cells by directly activating RNase L with 2-5A or  
314 introducing RNase L-cleaved small RNAs and compared to control small RNAs. The 2-  
315 5A-induction of CCL5 (RANTES), IL-8 or IP-10 promoter in G3BP1 KO cells was

316 comparable to that of control WT cells (Fig. 6A). Consistent with the observation that  
317 RNase L-cleaved small RNAs promoted inflammasome signaling, we observed increase  
318 in promoter activation in cells treated with these RNAs compared to control small RNAs.  
319 As with 2-5A treatment, depleting G3BP1 in cells did not affect induction of CCL5  
320 (RANTES), IL-8 or IP-10 promoter by RNase L-cleaved small RNAs in promoter-driven  
321 luciferase assays (Fig. 6B). Similar increase in mRNA levels of CCL5 (RANTES), IL-8 or  
322 IP-10 as well as CXCL1 was observed in response to 2-5A and RNase L-cleaved RNAs  
323 in control WT cells and depletion of G3BP1 did not affect mRNA levels as determined by  
324 real-time PCR analysis (Fig. 6C, D). To further analyze if Tumor Necrosis Factor alpha  
325 (TNF $\alpha$ )-induced cytokines are affected by SGs, we compared CCL5 (RANTES), IL-8 or  
326 IP-10 promoter induction in response to TNF $\alpha$  in G3BP1 KO and control WT cells. No  
327 significant difference in promoter induction of TNF- $\alpha$ -induced cytokines was observed in  
328 cells lacking G3BP1 (Fig. 6E). These results show that while RNase L activation and the  
329 RNA cleavage products induce proinflammatory cytokines, unlike IFN- $\beta$  production, avSG  
330 induced by RNase L is not required for this effect as cells lacking key SG protein, G3BP1,  
331 induce comparable levels of these cytokines.

### 332 **Antiviral stress granule assembly restricts SeV replication**

333 RNase L contributes to IFN- $\beta$  production during Sendai virus (SeV) infection and SeV is  
334 susceptible to RNase L antiviral effects (46). We tested the hypothesis that SeV infection  
335 induces avSG formation with antiviral roles in infected cells. Virus infected cells were  
336 detected by immunostaining using anti-SeV antibodies for structural proteins 24h post  
337 infection and SG formation was monitored by appearance of G3BP1 puncta (Fig. 7A). To  
338 biochemically characterize the SG formed during SeV infection as avSG, we purified

339 avSG core from infected cells and co-immunoprecipitated antiviral proteins that interacted  
340 with G3BP1 and compared to uninfected cells. As with avSG formation in RNase L-  
341 activated cells, G3BP1 interacted with Rig-I and PKR in avSG core only during infection  
342 and OAS and RNase L localized to avSG but did not interact with G3BP1(Fig. 7B). We  
343 blocked formation of avSG to demonstrate the significance during SeV infection using  
344 cells lacking G3BP1, a protein critical for avSG assembly. To further understand the role  
345 of RNase L-induced avSG, we used RNase L KO cells and compared SeV RNA copies  
346 produced during the time course of SeV infection up to 36h. In G3BP1 KO cells increase  
347 in SeV RNA copies was observed at 24h and further increased to 2.8-fold by 36h  
348 compared to control WT cells (Fig. 7C). Consistent with previous studies, RNase L KO  
349 cells were more permissive to SeV replication and SeV RNA copies were 5-fold more at  
350 24h and a log higher 36h post infection (Fig. 7D). Increase in viral titers in both G3BP1  
351 and RNase L KO cells correlated with increased accumulation of SeV proteins during time  
352 course of infection on immunoblots probed with anti-SeV antibodies (Fig. 7E). The  
353 increase in viral titers correlated with decrease in IFN- $\beta$  produced during SeV infection in  
354 G3BP1 KO and RNase L KO cells demonstrating the importance of both antiviral role of  
355 RNase L as well as avSG assembly in SeV replication (Fig. 7F, G).

## 356 **DISCUSSION**

357 RNase L is a regulated endoribonuclease that is activated in virus-infected cells by a  
358 unique ligand, 2-5A ( $(p5'A(2'p5'A))_n$ ;  $x = 1-3$ ;  $n \geq 2$ ), to produce cleavage products which  
359 are predominantly double-stranded with 5' hydroxyl and 2',3'-cyclic phosphate ends (55).  
360 RNase L-cleaved dsRNA activate signaling pathways by binding to diverse RNA-binding  
361 proteins to induce IFN- $\beta$ , activate inflammasome, induce autophagy or promote switch



362 from autophagy to apoptosis. Previous studies showed that RNase L cleavage products  
363 amplify IFN- $\beta$  production through Rig-I and or MDA5 via MAVS (IPS-1) signaling pathway  
364 to sustain antiviral response, but how the cells coordinate RNA sensing to signaling  
365 response remains unclear (46). Our results show that RNase L activation induces antiviral  
366 stress granules (avSGs) containing key stress granule protein, G3BP1 and antiviral  
367 dsRNA binding proteins Rig-I, PKR, OAS as well as RNase L which are distinct from  
368 canonical SGs formed during oxidative stress (56). Using Crispr/Cas9 knockout cells our  
369 data suggests these dsRNAs products activate PKR and subsequent phosphorylation of  
370 eIF2 $\alpha$  induces avSGs consistent with accumulation of dsRNA in SG with G3BP1 in  
371 response to 2-5A. Biochemical analysis of avSG using purified SG revealed interaction  
372 of G3BP1 with Rig-I and PKR, which is consistent with avSG assembled in response to  
373 virus infection and dsRNA (35, 36, 39-41). OAS and RNase L, while present in avSG  
374 core, do not physically interact with G3BP1. Finally, we demonstrate the unique  
375 requirement of avSG assembly during RNase L activation for IRF3-mediated IFN- $\beta$   
376 induction but not IFN signaling or induction of proinflammatory cytokines. Consequently,  
377 cells lacking avSG (G3BP1 KO) or RNase L signaling (RNase L KO) produced  
378 significantly less IFN during SeV infection and much higher viral titers due to  
379 compromised antiviral response. We propose that during viral infection, RNase L  
380 contributes cleaved dsRNAs to induce avSG that anchor antiviral dsRNA-binding proteins  
381 to provide a platform for efficient interaction of RNA ligands with pattern recognition  
382 receptors like Rig-I to enhance IFN- $\beta$  production and antiviral response.

383 In our study, we have transfected cells with 2-5A, a specific ligand to directly activate  
384 RNase L and monitored formation of unique SG described as avSG based on the

385 recruitment of dsRNA-binding antiviral proteins like Rig-I, PKR, OAS and RNase L.  
386 RNase L enzyme activity was required for avSG formation as RNase L KO cells  
387 reconstituted with functional enzyme restored avSG formation while mutant RNase L that  
388 lacked nuclease activity did not. Similar to other reports, oxidative stress by H<sub>2</sub>O<sub>2</sub>  
389 treatment induced canonical SG formation that did not recruit antiviral proteins (56, 57).  
390 RNase L cleaves single-stranded viral and cellular RNAs after UU or UA residues leaving  
391 5'-hydroxyl and 2',3'-cyclic phosphate termini on dsRNAs which are required for IFN  
392 induction (46). PKR was activated by RNase L-cleaved RNAs by phosphorylating eIF2 $\alpha$   
393 which in turn induced avSG formation. PKR KO cells lacked phospho-eIF2 $\alpha$  in response  
394 to RNase L-cleaved RNAs which correlated with lack of avSG formation, while cells  
395 lacking Rig-I had no effect. These results suggest that PKR is required for nucleation of  
396 avSG by RNase L. Introducing RNA cleavage products into RNase L KO cells restored  
397 avSG formation similar to control WT cells providing further evidence that RNase L-  
398 cleaved RNAs are inducers of avSG by activating PKR. Removal of the 2',3'-cyclic  
399 phosphate termini which was required for IFN induction, decreased avSG formation  
400 demonstrating correlation of avSG formation and IFN inducing abilities. Also, dsRNA  
401 accumulated and co-localized with G3BP1 in SGs in cells treated with 2-5A. These results  
402 are consistent with avSG formed in response to IAV $\Delta$ NS1, NDV, EMCV, SINV,  
403 adenovirus and Hepatitis C virus infection (26, 39, 58, 59). In other studies, formation of  
404 avSG was also observed following transfection with synthetic dsRNA, polyI:C which has  
405 broader effect by binding PKR, Rig-I or OAS isoforms (60). Binding OAS results in 2-5A  
406 production from cellular ATP that is the ligand for RNase L (10).

407 A recent report showed formation of unique RNase L-dependent bodies (RLB) distinct  
408 from SG in cells treated with polyI:C (61). The RLB they identify is distinct from avSGs  
409 we observe in that RLBs were formed with polyI:C treatment in cells lacking G3BP1 and  
410 was independent of SG, and did not require PKR or phosphorylation of eIF2 $\alpha$  which were  
411 essential in our study for avSG formation. Also, the study did not explore if antiviral  
412 proteins localized with RLBs they observed. These differences may be attributed to the  
413 use of polyI:C that can bind and activate other dsRNA-binding proteins as described  
414 above. Furthermore, response to polyI:C varies in cell-type dependent manner, levels of  
415 OAS isoforms as well as abundance of polyI:C-binding proteins in cells (62). Recent  
416 reports show the role of RNase L in widespread mRNA degradation and translation  
417 repression of select basal mRNAs while antiviral mRNAs escaped decay and robustly  
418 translated (63, 64). These results suggest that RNA signaling and decay pathways  
419 activated by RNase L are complex and the dynamics may vary based on specific activation  
420 of RNase L by 2-5A compared to indirect activation by polyI:C as well as cell type  
421 differences and abundance of dsRNA-binding proteins including OAS isoforms.

422 We characterized the biochemical nature of avSG formed during RNase L activation using  
423 2-5A, RNase L-cleaved RNAs and SeV infection by adapting a recently published SG  
424 purification method and determined interaction among proteins recruited to avSG. Our  
425 studies avoided overexpression of G3BP1 which forms SG independent of stimulus by  
426 testing interaction with endogenous G3BP1 (51). Interestingly, only PKR and Rig-I  
427 interacted with G3BP1 while OAS and RNase L localized but did not interact. Recent  
428 studies have shown that mature stress granule cores recruit a shell that generates a  
429 liquid-liquid phase separation from the cytosol and forms a scaffold dominated by weak

430 RNA-protein interactions (65). Further detailed analysis will be required to determine if  
431 OAS and RNase L are present in the shell that is dynamic while PKR and Rig-I interact  
432 with G3BP1 in the inner stable core. Several other RNA helicases like DHX36, DDX3,  
433 DDX6 and antiviral proteins like ADAR1, ZAP, cGAS and Trim25 localize in avSG  
434 suggesting crosstalk between stress, RNA signaling and antiviral pathways. Future  
435 studies will address the recruitment of these additional proteins and RNA ligands in avSG  
436 and their relevance during broad range of viral infections.

437 Cellular and viral RNA cleavage products generated by RNase L signal to IFN- $\beta$  gene  
438 through Rig-I/MDA5/MAVS (IPS-1) and IRF3 signaling pathway and here we showed  
439 involvement in inducing avSG. We demonstrate requirement of G3BP1, and thereby  
440 avSG, in IRF3 activation and IFN production using G3BP1 KO cells. RNA cleavage  
441 products are primarily responsible for avSG formation and IFN- $\beta$  induction as introduction  
442 into RNase L KO cells induced IFN- $\beta$  while control RNAs had no effect. In response to  
443 viral infection, activated Rig-I interacts with MAVS (IPS-1) and is redistributed on  
444 mitochondria (17, 66). Accordingly, MAVS (IPS-1) did not localize in avSG in our study  
445 consistent with similar lack of co-localization of Rig-I-containing avSG with MAVS  
446 aggregates following IAV $\Delta$ NS1 infection (35). Overexpression of MAVS (IPS-1) activated  
447 downstream signaling to activate IRF3 and induced IFN- $\beta$  independent of G3BP1 (Fig.  
448 4F) and did not induce avSG indicating avSG functions upstream of MAVS-signaling and  
449 IRF3 activation. Other stress-induced pathways, like oxidative stress, do not induce avSG  
450 formation or signaling events as we have shown leading to IFN production further  
451 demonstrating the distinct nature of avSG and signaling pathways activated. AvSG  
452 assembly is not required for IFN-signaling as IFN treatment induced ISG transcription in

453 cells lacking G3BP1 like control WT cells. No difference in nuclear translocation of  
454 phospho-STAT1 that is required for type I IFN signaling was observed in G3BP1 KO cells  
455 compared to control WT cells consistent with the role of avSG as a scaffold to recruit RNA  
456 sensors and PAMPs for signaling. RNase L also induces proinflammatory cytokines and  
457 unexpectedly, cells lacking G3BP1 induced similar levels of proinflammatory cytokines in  
458 response to 2-5A and RNase L-cleaved RNAs. Induction of cytokines by TNF $\alpha$  was also  
459 unaffected by lack of G3BP1. Consistent with our data, in prior studies, RNase L-cleaved  
460 RNAs stimulated NLRP3 complex formation and inflammasome activation to produce IL-  
461 1 $\beta$  by binding RNA helicase DHX33 and MAVS (IPS-1). Inflammasome activation was  
462 dependent on 2',3'-cyclic phosphate termini on these RNAs and independent of both Rig-  
463 I and MDA5, but required MAVS (IPS-1) (47). Taken together, these results show a  
464 unique requirement of avSG for IRF3-mediated IFN production distinct from  
465 proinflammatory cytokines. Both studies demonstrate bifurcation of RNA-signaling  
466 pathways for proinflammatory cytokines from IFN production and appear to be  
467 independent of Rig-like receptors but dependent on MAVS (IPS-1). In other studies,  
468 overexpression of GFP-G3BP1 in HeLa and U2OS cells induced SGs localizing innate  
469 immune proteins and regulated transcription through NF- $\kappa$ B and JNK along with  
470 expression of cytokines (41). It is not clear if RNA ligand-induced avSG formation differ  
471 from overexpression of G3BP1 and if specific recruitment of PRRs result in specific  
472 activation of interferon vs other cytokines. Further detailed analysis of the biochemical  
473 features of the RNA ligands and the receptors will clarify how these pathways are  
474 specifically activated.

475 RNase L contributes to IFN- $\beta$  production in vivo during SeV infection (46). Similar to  
476 RNase L KO cells, we observed reduced IFN- $\beta$  production in cells lacking G3BP1 during  
477 SeV infection. And, SeV infection induced SG formation which we characterized as avSG  
478 following purification and recruitment of PKR, Rig-I, OAS and RNase L (Fig. 7A, B).  
479 Reduced levels of IFN- $\beta$  production facilitated higher replication of SeV in both RNase L  
480 KO and G3BP1 KO cells with loss of antiviral effect. A recent study suggests that G3BP1  
481 inhibits SeV and VSV replication by suppressing RNF125-mediated ubiquitination of Rig-  
482 I resulting in increased Rig-I expression and IFN production (53). These observations  
483 suggest that G3BP1 may regulate host response to viral infections at multiple levels by  
484 regulating activity of PRRs like Rig-I as well as nucleating avSG formation. Prior studies  
485 showed that SeV infection produces highly structured dsRNA copy-back intermediates  
486 (defective viral genomes, DVG) with enhanced immunostimulatory activity (67). DVGs  
487 bind Rig-I and trigger expression of type I IFN and proinflammatory cytokines in infected  
488 cells (68). Another report identified unusual RNA species produced by various SeV strains  
489 with IFN-inducing abilities that correlated with SG-like structures (69). While not explored  
490 in this study, we speculate that highly structured RNA motifs present in DVGs are  
491 released by RNase L activity similar to RNA PAMPs produced from the 3' region of HCV  
492 genome during HCV infection to sustain IFN production (70).

493 RNase L has antiviral effects against broad range of RNA and DNA viruses. We  
494 demonstrate a role for RNase L-cleaved RNAs in inducing stress granules to serve as an  
495 antiviral signaling hub by coordinating interaction of RNA ligands with pattern recognition  
496 receptors (PRRs) to amplify IFN production and effectively mount antiviral response. It is  
497 likely that RNase L-cleaved RNAs are eventually turned over in P-bodies harboring

498 mRNA decay machinery to prevent sustained activation. Further studies will evaluate the  
499 role of RNase L-induced avSG in pathogenesis of viruses susceptible to RNase L antiviral  
500 effect and the broader impact on virus infection. Also, viruses antagonize host response  
501 and SG assembly to promote replication in host cells. Critical balance of host stress  
502 response pathways and viral manipulation of these pathways eventually dictates the  
503 outcome of viral infections.

## 504 **MATERIALS AND METHODS**

### 505 **Chemicals, reagents and antibodies**

506 Chemicals, unless indicated otherwise, were from Sigma Aldrich (St. Louis, MO, USA).  
507 Antibodies against G3BP1 (SC-81940), OAS1 (SC-98424), OAS2 (SC-374238), RNase  
508 L (SC-22870), PKR (SC-707) and RIG-I (SC-48931) were from Santa Cruz  
509 Biotechnology; G3BP1 (A302-033A) used for immunoprecipitation was from Bethyl  
510 laboratories; Sendai virus (MBL-PD029) was from MBL; FLAG (14793), phospho-eIF2 $\alpha$   
511 (3398), eIF2 $\alpha$  (5324), Histone H3 (9715), Lamin A/C (4777), phospho-IRF3 (4947), IRF3  
512 (4302), phospho-STAT1 (9167), STAT1 (9172), ISG56 (14769) and  $\beta$ -actin (3700) were  
513 from Cell Signaling Technology; Recombinant human TNF- $\alpha$  (PHC3011) and antibody  
514 against OAS3 (PA5-31090) was from Thermo Fisher Scientific; RIG-I (ALX-804-849-  
515 C100) and MAVS (ALX-210-929-C100) were from Enzo Life Sciences; phospho-PKR  
516 (AB81303) and total-PKR (1511-1) were from Abcam; monoclonal antibody to human  
517 RNase L was kindly provided by Robert Silverman (Cleveland Clinic); dsRNA (J2) was  
518 from English & Scientific Consulting. Anti-mouse IgG and anti-rabbit IgG HRP linked  
519 secondary antibodies were from Cell Signaling Technology and ECL reagents were from  
520 Boston Bioproducts and GE Healthcare. Interferon  $\beta$  was from Biogen Idec. Hydrogen

521 peroxide (H325-100) and puromycin (BP2956100) was purchased from Fisher scientific.  
522 2–5A was prepared enzymatically from ATP and recombinant 2–5A synthetase (a  
523 generous gift from Rune Hartmann, University of Aarhus, Aarhus, Denmark) as described  
524 previously (71).

## 525 **Cell culture and transfections**

526 The human fibrosarcoma cell line, HT1080 (a gift from Ganes Sen, Cleveland Clinic,  
527 Cleveland, OH, USA) were cultured in Dulbecco's modified minimal essential medium  
528 with 10% fetal bovine serum, 100 µg/mL penicillin/streptomycin, 2 mM L-glutamine, and  
529 non-essential amino acids. Cells were maintained in 95% air, 5% CO<sub>2</sub> at 37°C.  
530 Transfection of 2-5A (10µM) was performed using lipofectamine 2000 (Invitrogen,  
531 Carlsbad, CA, USA) according to manufacturer's protocol. RNase L cleaved small RNAs  
532 and control small RNAs were prepared as previously (46, 72) and transfected (2µg/ml)  
533 using Polyjet reagent (SignaGen Laboratories) according to manufacturer's protocol.  
534 H<sub>2</sub>O<sub>2</sub> (1µM) was added to cell culture media for 3 hours to induce oxidative stress.

## 535 **Generation of cells with *PKR*, *Rig-I*, *RNase L* and *G3BP1* knockout using** 536 **CRISPR/Cas9 system.**

537 Knockout cells were generated using CRISPR/Cas 9 system (72, 73). Small guide RNAs  
538 (sgRNA) (Table 1, supplementary data) were designed using (8)  
539 <https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design>. The guide RNA  
540 sequences were synthesized as DNA oligonucleotides and annealed, phosphorylated  
541 and ligated into the vector pSpCas9(BB)-2A-Puro (PX459 Addgene plasmid #62988)  
542 V2.0 (a gift from Feng Zhang) that was prepared by digestion with BsmBI. HT1080 cells



543 (3×10<sup>5</sup> cells/well of a 6-well plate) were transfected with 2µg resulting plasmids and  
544 selected in (1µg/ml) puromycin. Clones were obtained by limiting dilution and gene knock-  
545 out colonies were validated by immunoblot and sequencing (Fig S1).

#### 546 **Plasmids**

547 Plasmids Flag-RNase L, Flag-RNase L R667A (Robert Silverman, Cleveland Clinic),  
548 GFP-IRF3 (Travis Taylor, University of Toledo), HA-IPS-1(MAVS) (Invivogen), IFN-β-luc  
549 (Michael Gale, University of Washington), ISG56-luc (Ganes Sen, Cleveland Clinic),  
550 ISG15-luc (Bret Hassel, University of Maryland), IP10-luc, IL-8-luc (George Stark,  
551 Cleveland Clinic), CCL5-luc, IRF3-Gal/UAS-luc (Katherine Fitzgerald, University of  
552 Massachusetts) were transfected using Polyjet reagent as per manufacturer's  
553 instructions.

#### 554 **Western blot analysis**

555 The cells were lysed in NP-40 lysis buffer containing 0.5% NP-40, 90 mM KCl, 5 mM  
556 magnesium acetate, 20 mM Tris, pH 7.5, 5 mM β-mercaptoethanol, 0.1 M  
557 phenylmethylsulfonyl fluoride (PMSF), 0.2 mM sodium orthovanadate, 50 mM NaF, 10  
558 mM glycerophosphate, protease inhibitor (Roche Diagnostics). The lysates were clarified  
559 by centrifugation at 10,000×g (4°C for 20 min). Protein (15–100 µg per lane) was  
560 separated in polyacrylamide gels containing SDS and transferred to Nitrocellulose  
561 membrane (Biorad) and probed with different primary antibodies according to the  
562 manufacturer's protocols. Membranes were incubated with goat anti-mouse or goat anti-  
563 rabbit antibody tagged with horseradish peroxidase (Cell Signaling) and immunoreactive  
564 bands were detected by enhanced chemiluminescence (GE Healthcare and Boston

565 Bioproducts). Images were processed using Adobe Photoshop CS4 (Adobe, San Jose,  
566 CA, USA). In some instances, nonspecific lanes were cropped to generate the images  
567 and the boundaries are indicated in representative figures.

### 568 **Immunofluorescence analysis**

569 Cells were cultured on glass coverslips and after treatment, cells were fixed with 4%  
570 paraformaldehyde (Boston Bioproducts) for 15 minutes and permeabilized with 0.1%  
571 Triton X-100 in PBS for 15 minutes. Cells were then blocked with 3% BSA for 1 hour at  
572 room temperature and incubated overnight at 4°C with indicated antibodies. Alexa488- or  
573 Alexa647-conjugated anti-immunoglobulin antibody (Molecular Probes) were used as  
574 secondary antibodies. Cell nuclei were stained with Vectashield with DAPI to stain the  
575 nucleus (Vector Labs). Fluorescence and confocal microscopy assessments were  
576 performed with Leica CS SP5 multi-photon laser scanning confocal microscope (Leica  
577 Microsystems). All subsequent analysis and processing of images were performed using  
578 the LAS AF software (Leica Microsystems). Cells containing avSG ( $n > 5$ ) which are above  
579 0.6 $\mu$ m in diameter were considered for analysis. The percentage of avSG containing cells  
580 were calculated in at least five random fields from a minimum of 100 cells per treatment.  
581 Colocalization of proteins in stress granules were assessed by line scan analysis using  
582 Image J as described (74). A line was drawn across the stress granules and the intensity  
583 were measured using plot profile. The arbitrary intensity was plotted according to arbitrary  
584 distance for each channel.

### 585 **RNA isolation, rRNA cleavage assay and Quantitative real-time PCR**

586 Total RNA was isolated from cells using Trizol reagent (Invitrogen), as per manufacture  
587 instructions and resolved on RNA chips using Bioanalyzer 2100 (Agilent Technologies)  
588 as described previously (71). RNase L cleaved small RNAs, CIP treated RNase L-cleaved  
589 small RNAs and control small RNAs were purified as described earlier (46, 71). Reverse  
590 transcription and cDNA synthesis was performed using random decamers and a  
591 RETROscript cDNA synthesis kit (Life Technologies; Thermo Fisher Scientific). Gene  
592 expression was determined by quantitative reverse transcription polymerase chain  
593 reaction (qRT-PCR) using SYBR Green PCR Master Mix (Bio-Rad Laboratories Inc.,  
594 Hercules, CA, USA) using the gene-specific primers (Table 2, supplementary data) and  
595 normalized to GAPDH expression.

#### 596 **Luciferase assay**

597 Cells ( $1 \times 10^5$ ) were seeded in 12-well plate and transfected with indicated plasmids along  
598 with pCH110  $\beta$ -galactosidase expressing plasmid to normalize transfection efficiency.  
599 Cells were harvested at indicated time points in luciferase lysis buffer and luciferase  
600 activity was determined using luciferase reagents (Goldbio, USA) and normalized to  $\beta$ -  
601 galactosidase levels (75).

#### 602 **Stress granules isolation and immunoprecipitation**

603 Stress granules were isolated as described before (51). Briefly, cells were grown on six  
604 10cm dishes and after stress, cells were pelleted at  $1500 \times g$  for 3 min. Upon removal of  
605 media, pellets were immediately flash-frozen in liquid N<sub>2</sub> and stored at  $-80^\circ\text{C}$  until  
606 isolation of the stress granule core was performed. Cell pellet was thawed on ice for 5  
607 min, resuspended in 1ml of SG lysis buffer (50 mM Tris-HCl (pH 7.4), 100 mM potassium

608 acetate, 2 mM magnesium acetate, 0.5 mM dithiothreitol, 50 µg/ml heparin, 0.5% NP-40,  
609 EDTA-free protease inhibitor, 1 U/µl of RNasin plus RNase inhibitor (Promega) and  
610 passed through a 25-gauge 5/8 needle attached to 1ml syringe 10 times. After lysis,  
611 lysates were spun for 5 mins at 1000×g at 4°C to remove cell debris. Supernatant was  
612 spun at 18,000×g for 20 mins at 4°C to pellet SG core. The resulting supernatant was  
613 discarded, and pellet was resuspended in 1ml of SG lysis buffer and spun at 18,000×g  
614 for 20 mins at 4°C. The resulting pellet was resuspended in 300µl of SG lysis buffer and  
615 spun at 850×g for 2 mins at 4°C. The supernatant which represents the SG core enriched  
616 fraction was transferred to new tube. Equal amounts of SG core was subject to  
617 immunoprecipitation using anti-G3BP1 antibody (1ug) and isotype specific control  
618 antibody and protein A-sepharose beads (Sigma-Aldrich). Samples were incubated at  
619 4°C overnight on a rotator and immune complexes recovered by centrifugation and five  
620 washes in buffer. Samples were boiled in SDS-sample buffer and analyzed by protein gel  
621 electrophoresis and immunoblotting using indicated antibodies.

## 622 **Viral growth kinetics**

623  $5 \times 10^5$  cells were plated in a 6-well plate and next day, cells were infected with Sendai  
624 virus (Cantell strain) at 40HAU/ml in media without serum. After 1 hour, media was  
625 replaced with complete media and cells were harvested at indicated time points.  
626 Expression of viral antigen was determined on western blots using anti-Sendai virus  
627 antibody. Total RNA was isolated from infected cells using TRIzol reagent (Invitrogen) or  
628 QIAmp viral RNA kit (Qiagen) and qRT-PCR was performed to quantify viral RNA copy  
629 number as described previously (71).

## 630 **Statistical analysis**

631 All values are presented as mean  $\pm$  SEM from at least three independent experiments  
632 or are representative of three independent experiments performed in triplicate and  
633 shown as mean  $\pm$  SD. Student's t-tests were used for determining statistical significance  
634 between groups using Prism8 (GraphPad) software and  $p < 0.05$  was considered  
635 significant.

## 636 **SUPPLEMENTARY MATERIALS**

637 Fig. S1

638 Table 1

639 Table 2

## 640 **ACKNOWLEDGEMENTS**

641 We thank Robert Silverman, Ganes Sen and George Stark (Cleveland Clinic) for  
642 providing cells, plasmids and antibodies used in this study. This work was supported by  
643 National Institutes of Health (NIH) Grants AI119980-01A1 (KM), internal grants (KM) and  
644 startup funds from University of Toledo (KM). We thank Scott Leisner (University of  
645 Toledo), Saurabh Chattopadhyay (University of Toledo) and Travis Taylor (University of  
646 Toledo) for valuable discussions through the course of this work.

## 647 **CONFLICTS OF INTEREST**

648 The authors declare no conflict of interest. The funders had no role in the design of the  
649 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript,  
650 or in the decision to publish the results.

## 651 **REFERENCES**

- 652 1. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. *Nat Immunol*  
653 7:131-7.
- 654 2. Kawai T, Akira S. 2011. Regulation of innate immune signalling pathways by the  
655 tripartite motif (TRIM) family proteins. *EMBO Mol Med* 3:513-27.
- 656 3. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR.  
657 2007. Interferons at age 50: past, current and future impact on biomedicine. *Nat*  
658 *Rev Drug Discov* 6:975-90.
- 659 4. Koyama S, Ishii KJ, Coban C, Akira S. 2008. Innate immune response to viral  
660 infection. *Cytokine* 43:336-41.
- 661 5. Medzhitov R. 2007. TLR-mediated innate immune recognition. *Semin Immunol*  
662 19:1-2.
- 663 6. Loo YM, Gale M, Jr. 2011. Immune signaling by RIG-I-like receptors. *Immunity*  
664 34:680-92.
- 665 7. Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, Qin J, Cheng G, Liu  
666 YJ. 2011. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor  
667 molecule TRIF to sense dsRNA in dendritic cells. *Immunity* 34:866-78.
- 668 8. Yim HC, Williams BR. 2014. Protein kinase R and the inflammasome. *J Interferon*  
669 *Cytokine Res* 34:447-54.
- 670 9. Balachandran S, Barber GN. 2007. PKR in innate immunity, cancer, and viral  
671 oncolysis. *Methods Mol Biol* 383:277-301.
- 672 10. Silverman RH. 2007. A scientific journey through the 2-5A/RNase L system.  
673 *Cytokine Growth Factor Rev* 18:381-8.
- 674 11. Silverman RH. 2007. Viral encounters with 2',5'-oligoadenylate synthetase and  
675 RNase L during the interferon antiviral response. *J Virol* 81:12720-9.
- 676 12. Dempsey A, Bowie AG. 2015. Innate immune recognition of DNA: A recent history.  
677 *Virology* 479-480:146-52.
- 678 13. Hopfner KP. 2014. RIG-I holds the CARDs in a game of self versus nonself. *Mol*  
679 *Cell* 55:505-7.
- 680 14. Yoneyama M, Fujita T. 2009. RNA recognition and signal transduction by RIG-I-  
681 like receptors. *Immunol Rev* 227:54-65.
- 682 15. Jiang X, Kinch LN, Brautigam CA, Chen X, Du F, Grishin NV, Chen ZJ. 2012.  
683 Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates  
684 antiviral innate immune response. *Immunity* 36:959-73.
- 685 16. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. 2007.  
686 Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. *Proc*  
687 *Natl Acad Sci U S A* 104:7500-5.
- 688 17. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O,  
689 Akira S. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I  
690 interferon induction. *Nat Immunol* 6:981-8.
- 691 18. Seth RB, Sun L, Ea CK, Chen ZJ. 2005. Identification and characterization of  
692 MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and  
693 IRF 3. *Cell* 122:669-82.
- 694 19. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. 2005. VISA is an adapter protein  
695 required for virus-triggered IFN-beta signaling. *Mol Cell* 19:727-40.

- 696 20. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R,  
697 Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is  
698 targeted by hepatitis C virus. *Nature* 437:1167-72.
- 699 21. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle  
700 AJ, Liao SM, Maniatis T. 2003. IKKepsilon and TBK1 are essential components of  
701 the IRF3 signaling pathway. *Nat Immunol* 4:491-6.
- 702 22. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T.  
703 2004. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-  
704 deficient mouse embryonic fibroblasts. *Proc Natl Acad Sci U S A* 101:233-8.
- 705 23. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR,  
706 Barber GN. 2000. Essential role for the dsRNA-dependent protein kinase PKR in  
707 innate immunity to viral infection. *Immunity* 13:129-41.
- 708 24. Taylor SS, Haste NM, Ghosh G. 2005. PKR and eIF2alpha: integration of kinase  
709 dimerization, activation, and substrate docking. *Cell* 122:823-5.
- 710 25. Anderson P, Kedersha N. 2008. Stress granules: the Tao of RNA triage. *Trends*  
711 *Biochem Sci* 33:141-50.
- 712 26. Onomoto K, Yoneyama M, Fung G, Kato H, Fujita T. 2014. Antiviral innate  
713 immunity and stress granule responses. *Trends Immunol* 35:420-8.
- 714 27. Youn JY, Dunham WH, Hong SJ, Knight JDR, Bashkurov M, Chen GI, Bagci H,  
715 Rathod B, MacLeod G, Eng SWM, Angers S, Morris Q, Fabian M, Cote JF, Gingras  
716 AC. 2018. High-Density Proximity Mapping Reveals the Subcellular Organization  
717 of mRNA-Associated Granules and Bodies. *Mol Cell* 69:517-532 e11.
- 718 28. Nover L, Scharf KD, Neumann D. 1989. Cytoplasmic heat shock granules are  
719 formed from precursor particles and are associated with a specific set of mRNAs.  
720 *Mol Cell Biol* 9:1298-308.
- 721 29. Piotrowska J, Hansen SJ, Park N, Jamka K, Sarnow P, Gustin KE. 2010. Stable  
722 formation of compositionally unique stress granules in virus-infected cells. *J Virol*  
723 84:3654-65.
- 724 30. Williams BR. 2001. Signal integration via PKR. *Sci STKE* 2001:re2.
- 725 31. Buchan JR, Parker R. 2009. Eukaryotic stress granules: the ins and outs of  
726 translation. *Mol Cell* 36:932-41.
- 727 32. Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R. 2016. ATPase-  
728 Modulated Stress Granules Contain a Diverse Proteome and Substructure. *Cell*  
729 164:487-98.
- 730 33. Wheeler JR, Matheny T, Jain S, Abrisch R, Parker R. 2016. Distinct stages in  
731 stress granule assembly and disassembly. *Elife* 5.
- 732 34. Hu S, Sun H, Yin L, Li J, Mei S, Xu F, Wu C, Liu X, Zhao F, Zhang D, Huang Y,  
733 Ren L, Cen S, Wang J, Liang C, Guo F. 2019. PKR-dependent cytosolic cGAS foci  
734 are necessary for intracellular DNA sensing. *Sci Signal* 12.
- 735 35. Onomoto K, Jogi M, Yoo JS, Narita R, Morimoto S, Takemura A, Sambhara S,  
736 Kawaguchi A, Osari S, Nagata K, Matsumiya T, Namiki H, Yoneyama M, Fujita T.  
737 2012. Critical role of an antiviral stress granule containing RIG-I and PKR in viral  
738 detection and innate immunity. *PLoS One* 7:e43031.
- 739 36. Yoo JS, Takahashi K, Ng CS, Ouda R, Onomoto K, Yoneyama M, Lai JC, Lattmann  
740 S, Nagamine Y, Matsui T, Iwabuchi K, Kato H, Fujita T. 2014. DHX36 enhances

- 741 RIG-I signaling by facilitating PKR-mediated antiviral stress granule formation.  
742 PLoS Pathog 10:e1004012.
- 743 37. Rozelle DK, Filone CM, Kedersha N, Connor JH. 2014. Activation of stress  
744 response pathways promotes formation of antiviral granules and restricts virus  
745 replication. *Mol Cell Biol* 34:2003-16.
- 746 38. Thulasi Raman SN, Liu G, Pyo HM, Cui YC, Xu F, Ayalew LE, Tikoo SK, Zhou Y.  
747 2016. DDX3 Interacts with Influenza A Virus NS1 and NP Proteins and Exerts  
748 Antiviral Function through Regulation of Stress Granule Formation. *J Virol*  
749 90:3661-75.
- 750 39. Oh SW, Onomoto K, Wakimoto M, Onoguchi K, Ishidate F, Fujiwara T, Yoneyama  
751 M, Kato H, Fujita T. 2016. Leader-Containing Uncapped Viral Transcript Activates  
752 RIG-I in Antiviral Stress Granules. *PLoS Pathog* 12:e1005444.
- 753 40. Reineke LC, Kedersha N, Langereis MA, van Kuppeveld FJ, Lloyd RE. 2015.  
754 Stress granules regulate double-stranded RNA-dependent protein kinase  
755 activation through a complex containing G3BP1 and Caprin1. *mBio* 6:e02486.
- 756 41. Reineke LC, Lloyd RE. 2015. The stress granule protein G3BP1 recruits protein  
757 kinase R to promote multiple innate immune antiviral responses. *J Virol* 89:2575-  
758 89.
- 759 42. White JP, Cardenas AM, Marissen WE, Lloyd RE. 2007. Inhibition of cytoplasmic  
760 mRNA stress granule formation by a viral proteinase. *Cell Host Microbe* 2:295-  
761 305.
- 762 43. Panas MD, Varjak M, Lulla A, Eng KE, Merits A, Karlsson Hedestam GB,  
763 McInerney GM. 2012. Sequestration of G3BP coupled with efficient translation  
764 inhibits stress granules in Semliki Forest virus infection. *Mol Biol Cell* 23:4701-12.
- 765 44. Silverman RH, Skehel JJ, James TC, Wreschner DH, Kerr IM. 1983. rRNA  
766 cleavage as an index of ppp(A2'p)nA activity in interferon-treated  
767 encephalomyocarditis virus-infected cells. *J Virol* 46:1051-5.
- 768 45. Dong B, Silverman RH. 1995. 2-5A-dependent RNase molecules dimerize during  
769 activation by 2-5A. *J Biol Chem* 270:4133-7.
- 770 46. Malathi K, Dong B, Gale M, Jr., Silverman RH. 2007. Small self-RNA generated by  
771 RNase L amplifies antiviral innate immunity. *Nature* 448:816-9.
- 772 47. Chakrabarti A, Banerjee S, Franchi L, Loo YM, Gale M, Jr., Nunez G, Silverman  
773 RH. 2015. RNase L activates the NLRP3 inflammasome during viral infections.  
774 *Cell Host Microbe* 17:466-77.
- 775 48. Siddiqui MA, Mukherjee S, Manivannan P, Malathi K. 2015. RNase L Cleavage  
776 Products Promote Switch from Autophagy to Apoptosis by Caspase-Mediated  
777 Cleavage of Beclin-1. *Int J Mol Sci* 16:17611-36.
- 778 49. Manivannan P, Reddy V, Mukherjee S, Clark KN, Malathi K. 2019. RNase L  
779 Induces Expression of A Novel Serine/Threonine Protein Kinase, DRAK1, to  
780 Promote Apoptosis. *Int J Mol Sci* 20.
- 781 50. McCormick C, Khaperskyy DA. 2017. Translation inhibition and stress granules in  
782 the antiviral immune response. *Nat Rev Immunol* 17:647-660.
- 783 51. Wheeler JR, Jain S, Khong A, Parker R. 2017. Isolation of yeast and mammalian  
784 stress granule cores. *Methods* 126:12-17.



- 785 52. Kim SS, Sze L, Liu C, Lam KP. 2019. The stress granule protein G3BP1 binds viral  
786 dsRNA and RIG-I to enhance interferon-beta response. *J Biol Chem* 294:6430-  
787 6438.
- 788 53. Yang W, Ru Y, Ren J, Bai J, Wei J, Fu S, Liu X, Li D, Zheng H. 2019. G3BP1  
789 inhibits RNA virus replication by positively regulating RIG-I-mediated cellular  
790 antiviral response. *Cell Death Dis* 10:946.
- 791 54. Malathi K, Paranjape JM, Bulanova E, Shim M, Guenther-Johnson JM, Faber PW,  
792 Eling TE, Williams BR, Silverman RH. 2005. A transcriptional signaling pathway in  
793 the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. *Proc Natl*  
794 *Acad Sci U S A* 102:14533-8.
- 795 55. Chakrabarti A, Jha BK, Silverman RH. 2011. New insights into the role of RNase  
796 L in innate immunity. *J Interferon Cytokine Res* 31:49-57.
- 797 56. Aulas A, Fay MM, Lyons SM, Achorn CA, Kedersha N, Anderson P, Ivanov P.  
798 2017. Stress-specific differences in assembly and composition of stress granules  
799 and related foci. *J Cell Sci* 130:927-937.
- 800 57. Emara MM, Fujimura K, Sciaranghella D, Ivanova V, Ivanov P, Anderson P. 2012.  
801 Hydrogen peroxide induces stress granule formation independent of eIF2alpha  
802 phosphorylation. *Biochem Biophys Res Commun* 423:763-9.
- 803 58. Sun Y, Dong L, Yu S, Wang X, Zheng H, Zhang P, Meng C, Zhan Y, Tan L, Song  
804 C, Qiu X, Wang G, Liao Y, Ding C. 2017. Newcastle disease virus induces stable  
805 formation of bona fide stress granules to facilitate viral replication through  
806 manipulating host protein translation. *FASEB J* 31:1337-1353.
- 807 59. Berlanga JJ, Ventoso I, Harding HP, Deng J, Ron D, Sonenberg N, Carrasco L, de  
808 Haro C. 2006. Antiviral effect of the mammalian translation initiation factor 2alpha  
809 kinase GCN2 against RNA viruses. *EMBO J* 25:1730-40.
- 810 60. Zhang P, Li Y, Xia J, He J, Pu J, Xie J, Wu S, Feng L, Huang X, Zhang P. 2014.  
811 IPS-1 plays an essential role in dsRNA-induced stress granule formation by  
812 interacting with PKR and promoting its activation. *J Cell Sci* 127:2471-82.
- 813 61. Burke JM, Lester ET, Tauber D, Parker R. 2020. RNase L promotes the formation  
814 of unique ribonucleoprotein granules distinct from stress granules. *J Biol Chem*  
815 doi:10.1074/jbc.RA119.011638.
- 816 62. Li Y, Banerjee S, Wang Y, Goldstein SA, Dong B, Gaughan C, Silverman RH,  
817 Weiss SR. 2016. Activation of RNase L is dependent on OAS3 expression during  
818 infection with diverse human viruses. *Proc Natl Acad Sci U S A* 113:2241-6.
- 819 63. Burke JM, Moon SL, Matheny T, Parker R. 2019. RNase L Reprograms Translation  
820 by Widespread mRNA Turnover Escaped by Antiviral mRNAs. *Mol Cell* 75:1203-  
821 1217 e5.
- 822 64. Rath S, Prangley E, Donovan J, Demarest K, Wingreen NS, Meir Y, Korennykh A.  
823 2019. Concerted 2-5A-Mediated mRNA Decay and Transcription Reprogram  
824 Protein Synthesis in the dsRNA Response. *Mol Cell* 75:1218-1228 e6.
- 825 65. Cirillo L, Cieren A, Barbieri S, Khong A, Schwager F, Parker R, Gotta M. 2020.  
826 UBAP2L Forms Distinct Cores that Act in Nucleating Stress Granules Upstream of  
827 G3BP1. *Curr Biol* doi:10.1016/j.cub.2019.12.020.
- 828 66. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, Gale  
829 M, Jr. 2007. Regulation of innate antiviral defenses through a shared repressor  
830 domain in RIG-I and LGP2. *Proc Natl Acad Sci U S A* 104:582-7.

- 831 67. Mercado-Lopez X, Cotter CR, Kim WK, Sun Y, Munoz L, Tapia K, Lopez CB. 2013.  
832 Highly immunostimulatory RNA derived from a Sendai virus defective viral  
833 genome. *Vaccine* 31:5713-21.
- 834 68. Xu J, Mercado-Lopez X, Grier JT, Kim WK, Chun LF, Irvine EB, Del Toro Duany  
835 Y, Kell A, Hur S, Gale M, Jr., Raj A, Lopez CB. 2015. Identification of a Natural  
836 Viral RNA Motif That Optimizes Sensing of Viral RNA by RIG-I. *mBio* 6:e01265-  
837 15.
- 838 69. Yoshida A, Kawabata R, Honda T, Tomonaga K, Sakaguchi T, Irie T. 2015. IFN-  
839 beta-inducing, unusual viral RNA species produced by paramyxovirus infection  
840 accumulated into distinct cytoplasmic structures in an RNA-type-dependent  
841 manner. *Front Microbiol* 6:804.
- 842 70. Malathi K, Saito T, Crochet N, Barton DJ, Gale M, Jr., Silverman RH. 2010. RNase  
843 L releases a small RNA from HCV RNA that refolds into a potent PAMP. *RNA*  
844 16:2108-19.
- 845 71. Siddiqui MA, Malathi K. 2012. RNase L induces autophagy via c-Jun N-terminal  
846 kinase and double-stranded RNA-dependent protein kinase signaling pathways. *J*  
847 *Biol Chem* 287:43651-64.
- 848 72. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. 2013.  
849 Repurposing CRISPR as an RNA-guided platform for sequence-specific control of  
850 gene expression. *Cell* 152:1173-83.
- 851 73. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM.  
852 2013. RNA-guided human genome engineering via Cas9. *Science* 339:823-6.
- 853 74. Aulas A, Fay MM, Szaflarski W, Kedersha N, Anderson P, Ivanov P. 2017.  
854 Methods to Classify Cytoplasmic Foci as Mammalian Stress Granules. *J Vis Exp*  
855 doi:10.3791/55656.
- 856 75. Dayal S, Zhou J, Manivannan P, Siddiqui MA, Ahmad OF, Clark M, Awadia S,  
857 Garcia-Mata R, Shemshedini L, Malathi K. 2017. RNase L Suppresses Androgen  
858 Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in  
859 Prostate Cancer Cells. *Int J Mol Sci* 18.

860

## 861 **FIGURE LEGENDS**

862 **Figure 1. Activation of RNase L induces antiviral stress granules formation.** HT1080

863 cells were transfected with 2–5A (10  $\mu$ M) for 8h and (A) RNase L-mediated cleavage of

864 rRNA (arrows) was analyzed on RNA chips using the Agilent Bioanalyzer 2100, RNA

865 Integrity Number (RIN) is shown, (B) cells were fixed and stained with G3BP1 and

866 indicated antiviral proteins, the magnified images correspond to the boxed regions, (right)

867 intensity profiles of G3BP1 and antiviral proteins along the plotted lines as analyzed by

868 Image J line scan analysis and (C) the percentage of cells forming stress granules were  
869 quantitated. (D) RNase L KO cells were either mock transfected or transfected with FLAG-  
870 WT-RNase L or FLAG-R667A-RNase L and immunostained for G3BP1 and FLAG, (right)  
871 intensity profiles of G3BP1 and FLAG along the plotted lines as analyzed by Image J line  
872 scan analysis. HT1080 cells were treated with H<sub>2</sub>O<sub>2</sub> (1 mM) for 3h and (E) the percentage  
873 of cells forming stress granules were quantitated, (F) cells were immunostained with  
874 G3BP1 and indicated antiviral proteins (right) intensity profiles of G3BP1 and antiviral  
875 proteins along the plotted lines as analyzed by Image J line scan analysis. All experiments  
876 included at least 100 cells from three replicates. Scale bars correspond to 10µm. Data  
877 are representative of at least three independent experiments. \*p<0.01, \*\*p<0.001

878 **Figure 2. Involvement of PKR in RNase L-mediated avSG formation.** (A) HT1080 cells  
879 were treated with RNase L-cleaved small RNAs or control small RNAs (2µg/ml) and  
880 phosphorylation of PKR was detected in immunoblots, (B) WT and PKR KO cells were  
881 treated with control small RNAs or RNase L-cleaved small RNAs (2µg/ml ) for 8h and  
882 phosphorylation of eIF2α levels were determined in immunoblots, (C) CRISPR/Cas9  
883 knock-out of G3BP1, RIG-I, PKR, RIG-I/PKR or RNase L was verified in cell lysates by  
884 immunoblotting using specific antibodies, (D) Indicated cells were treated with 10µM of  
885 2-5A, 2µg/ml of control small RNAs, 2µg/ml RNase L-cleaved small RNAs or 2µg/ml of  
886 CIP treated RNase L-cleaved small RNAs for 8h, (E) the percentage of cells forming  
887 stress granules were quantitated. (F) Indicated cells were treated with 1mM H<sub>2</sub>O<sub>2</sub> for 3  
888 hours and stress granule formation analyzed by staining for G3BP1, and the percentage  
889 of cells forming stress granules were quantitated. (G) HT1080 cells were treated with 2-  
890 5A (10 µM) for 8h and cells were fixed and immunostained with G3BP1 and dsRNA, (right)

891 intensity profiles of G3BP1 and dsRNA along the plotted lines as analyzed by Image J  
892 line scan analysis. All experiments included at least 100 cells from three replicates. Data  
893 are representative of three independent experiments. Scale bars are 20 $\mu$ m. \*p<0.01, n.s:  
894 not significant, WT: Wild-Type.

895 **Figure 3. G3BP1 interacts with PKR and Rig-I in avSG, but not OAS and RNase L.**

896 (A) Schematic of avSG purification and analysis of fractions in immunoblots using  
897 indicated antibodies. HT1080 WT, G3BP1 KO or RNase L KO cells were treated with (B)  
898 mock or 10 $\mu$ M 2-5A, (C) RNase L-cleaved small RNAs or control small RNAs (2 $\mu$ g/ml),  
899 or (D) 1mM H<sub>2</sub>O<sub>2</sub> or mock treated and avSG was isolated as described in methods. The  
900 avSG core proteins were immunoprecipitated with G3BP1 antibody and immune complex  
901 analyzed for presence of PKR, Rig-I, OAS, RNase L and MAVS (IPS-1) by immunoblot  
902 analysis. Pellet and SG core fractions were probed for expression of G3BP1 and PKR,  
903 Rig-I, OAS, RNase L and MAVS (IPS-1). Nonspecific lanes were cropped to generate the  
904 image and the boundaries are indicated. Data are representative of results from two  
905 experiments. WT: Wild-Type.

906 **Figure 4. Antiviral SGs are required for IRF3-mediated IFN induction.** (A) HT1080

907 WT and G3BP1 KO cells (1 $\times$ 10<sup>5</sup>) were transfected with IFN- $\beta$ -luc, ISG15-luc or ISG56-  
908 luc reporter constructs along with  $\beta$ -galactosidase plasmids. After 24h, cells were treated  
909 with 10 $\mu$ M of 2-5A, 2 $\mu$ g/ml of RNase L-cleaved small RNAs or control small RNAs and  
910 8h later luciferase activity was measured and normalized to  $\beta$ -galactosidase levels. (B)  
911 HT1080 WT and G3BP1 KO cells were treated with 10 $\mu$ M of 2-5A, 2 $\mu$ g/ml of RNase L-  
912 cleaved small RNAs or control small RNAs and 8h later mRNA levels of IFN- $\beta$ , ISG15  
913 and ISG56 was measured by qRT-PCR and normalized to GAPDH mRNA levels. (C) WT

914 and G3BP1 KO cells were transfected with empty vector or HA-MAVS(IPS-1), IFN- $\beta$ -luc  
915 and  $\beta$ -galactosidase plasmids and after 24h, promoter activity was normalized to  $\beta$ -  
916 galactosidase levels. Effect of HA-MAVS on IFN- $\beta$  mRNA levels were determined by qRT-  
917 PCR and HA-MAVS expression was confirmed in immunoblots. HA-MAVS expressing  
918 cells were stained with G3BP1 to determine SG formation. (D) WT and G3BP1 KO cells  
919 were transfected with IRF3-GFP and 24h later cells were treated with 10 $\mu$ M of 2-5A or  
920 mock treated and imaged after 8h. The percentage of cells with nuclear GFP-IRF3 were  
921 calculated in random fields from a minimum of 100 cells and representative images are  
922 shown. WT and G3BP1 KO cells were transfected with IRF3-GAL4 and UAS-luciferase  
923 plasmids and treated with (E) 10 $\mu$ M of 2-5A for 8h or (F) HA-MAVS. Cells were lysed and  
924 luciferase activity was measured. (G) WT, G3BP1 KO or RNase L KO cells were  
925 transfected with 10 $\mu$ M of 2-5A for indicated times and p-IRF3, p-PKR and p-STAT1 levels  
926 were determined in immunoblot and compared to unphosphorylated levels,  $\beta$ -actin was  
927 used to normalize loading. (H) WT and G3BP1 KO cells were transfected with 1mM H<sub>2</sub>O<sub>2</sub>  
928 for 3h and levels of p-PKR, p-eIF2 $\alpha$ , p-IRF3 were compared to unphosphorylated levels  
929 and induction of ISG56 were determined in immunoblots. Data represent mean  $\pm$  S.E. for  
930 three independent experiments. \* $p$ <0.01, \*\* $p$ <0.001, \*\*\* $p$ <0.0001, n.s: not significant,  
931 WT: Wild-Type.

932 **Figure 5. Effect of avSG formation on IFN signaling.** HT1080 WT and G3BP1 KO cells  
933 were (A) treated with IFN- $\beta$  (1000 U/ml) for 24h and mRNA levels of ISG15 and ISG56  
934 were measured and normalized to GAPDH by qRT-PCR, (B) transfected with ISG15-luc  
935 or ISG56-luc reporter constructs along with  $\beta$ -galactosidase plasmids and 24h later  
936 treated with IFN- $\beta$  (1000 U/ml) and luciferase activity were measured and normalized to

937  $\beta$ -galactosidase levels. (C) WT, G3BP1 KO and RNase L KO cells were treated with IFN-  
938  $\beta$  (1000 U/ml) for indicated times and cell lysates were analyzed for phosphorylation of  
939 STAT1 and induction of OAS2, OAS3 and ISG56 in immunoblots.  $\beta$ -actin was used to  
940 normalize loading. (D) WT, G3BP1 KO and RNase L KO cells were treated with IFN- $\beta$   
941 (1000 U/ml) for 16h and nuclear translocation of p-STAT1 was determined by  
942 immunofluorescence and nucleus was stained with DAPI, (right) quantification of p-  
943 STAT1 nuclear translocation from five random fields. Data represent mean  $\pm$  S.E. for  
944 three independent experiments. n.s: not significant, WT: Wild-Type.

945 **Figure 6. Induction of proinflammatory cytokines by RNase L is independent of**  
946 **avSG assembly.** WT and G3BP1 KO cells were transfected with CCL5-luc, IL-8-luc or  
947 IP-10-luc and  $\beta$ -galactosidase plasmids and 24h later treated with (A) 2-5A (10 $\mu$ M), (B)  
948 RNase L-cleaved small RNAs or control small RNAs and luciferase activity normalized to  
949  $\beta$ -galactosidase levels. WT and G3BP1 KO cells were transfected with (C) 2-5A (10 $\mu$ M),  
950 (D) RNase L-cleaved small RNAs or control small RNAs and mRNA levels of CCL5, IL-  
951 8, IP-10 and CXCL1 was measured by qRT-PCR and normalized to GAPDH mRNA  
952 levels, (E) WT and G3BP1 KO cells were transfected with CCL5-luc, IL-8-luc or IP-10-luc  
953 and  $\beta$ -galactosidase plasmids and 24h later treated with 100ng/ml of TNF $\alpha$  and luciferase  
954 activity normalized to  $\beta$ -galactosidase levels. Data represent mean  $\pm$  S.E. for three  
955 independent experiments. n.s: not significant, WT: Wild-Type.

956 **Figure 7. Antiviral roles of RNase L and G3BP1 during SeV infection.** WT cells were  
957 infected with SeV (40 HAU/ml) for 24h and (A) cells were fixed and stained with G3BP1  
958 and antibody against SeV, (B) avSG was purified as described in methods. The avSG  
959 core proteins were immunoprecipitated with G3BP1 antibody and immune complex

960 analyzed for presence of PKR, Rig-I, OAS and RNase L by immunoblot analysis. Pellet  
961 and SG core fractions were probed for expression of G3BP1 and PKR, Rig-I, OAS and  
962 RNase L. Nonspecific lanes were cropped to generate the image and the boundaries are  
963 indicated. Data are representative of results from two experiments. WT, G3BP1 KO or  
964 RNase L KO cells were infected with SeV (40HAU/ml) for indicated times and (C, D) viral  
965 titers were estimated by determining copy numbers of SeV genomic RNA strands in  
966 supernatants by qRT-PCR, (E) Expression of SeV antigens were detected using anti-  
967 Sendai-virus antibody, and (F, G) IFN- $\beta$  mRNA levels were measured by qRT-PCR and  
968 normalized to GAPDH mRNA levels. Data represent mean  $\pm$  S.E. for three independent  
969 experiments. \*\*p<0.001, \*\*\*p<0.0001, n.s: not significant, WT: Wild-Type.

970 **S1. Schematic presentation of the coding regions of RNase L, G3BP1, RIG-I, PKR**  
971 **and RIG-I/PKR dKO that are targeted by CRISPR-Cas9.** The reference sequences and  
972 the mutated sequence for each gene is shown, as confirmed by sequencing. The bold  
973 letters denote the protospacer (sgRNA binding site), the red letters indicate the PAM  
974 (protospacer adjacent motif).

975

976

977

978

979

980




Figure 1









Figure 2




**Figure 3**




**Figure 4**



**Figure 5**



**Figure 6**



**Figure 7**

```
REF ATGGGGCCACGCCTTTTATCCTCGCAGCGATTGCGGGGAGCGTGAAGCTGCTGAAACTTTTCCT
RNase L MUTATGGGGCCACGCCTTTTATCCTC-----GCTGCTGAAACTTTTCCT

REF CCCCAGGTTGAATTGACCAAAGCAATGGTATGGAGAAGCCTAGTCCCCTGCTGGTCGGGCGGGAATTTGTGA
G3BP1 MUTCCCCAGGTTGAATT-----GAATTTGTGA

REF TTCCAGGATTATATCCGGAAG-ACCC TGGACCCTACCTACA
RIG-I MUTTTCCAGGATTATATCCGGAAGAACCCTGGACCCTACCTACA
      ^

REF CTAATTCAGGACCTCCACATGA-TAGGAGGTAGGTTGC
PKR MUTCTAATTCAGGACCTCCACATGATTAGGAGGTAGGTTGC
      ^

RIG-I/ PKR dKO | REF TTCCAGGATTATATCCGGAAG-ACCC TGGACCCTACCTACA
                  | MUTTTCCAGGATTATATCCGGAAGAACCCTGGACCCTACCTACA
                  |      ^
                  | REF CTAATTCAGGACCTCCACATGA-TAGGAGGTAGGTTGC
                  | PKR MUTCTAATTCAGGACCTCCACATGATTAGGAGGTAGGTTGC
                  |      ^
```

Figure S1

989

**Table 1. sgRNA sequence for *RNase L*, *G3BP1*, *PKR* and *Rig-I* knockout using CRISPR/Cas9 system.**

Gene	Sequence	
<i>RNASEL</i>	Forward	5'-CACCGCAATCGCTGCGAGGATAAA-3'
	Reverse	5'-AAACTTTATCCTCGCAGCGATTGC-3'
<i>G3BP1</i>	Forward	5'-CACCGAATTCCCGCCCGACCAGCAG-3'
	Reverse	5'-AAACCTGCTGGTCCGGGCGGGAATTC-3'
<i>EIF2AK2</i> (PKR)	Forward	5'-CACCGCAGGACCTCCACATGATAGG-3'
	Reverse	5'-AAACCCTATCATGTGGAGGTCCTGC-3'
<i>DDX58</i> (RIG-I)	Forward	5'-CACCGGGATTATATCCGGAAGACCC-3'
	Reverse	5'-AAACGGGTCTTCCGGATATAATCCC-3'

990

**Table 2. Primer sequences for real time RT-PCR**

Gene	Sequence	
<i>IFNB1</i>	Forward	5'-GGAGGACGCCGCATTGAC-3'
	Reverse	5'-TGATAGACATTAGCCAGGAGGTTC-3'
<i>ISG15</i>	Forward	5'-TGCAGAACTGCATCTCCATC-3'
	Reverse	5'-TTCATGAGGCCGTATTCCTC-3'
<i>IFIT1</i> (ISG56)	Forward	5'-TACAGCAACCATGAGTACAA-3'
	Reverse	5'-TCAGGTGTTTCACATAGGC-3'
<i>CCL5</i>	Forward	5'-CCAGCAGTCGTCTTTGTCAC-3'
	Reverse	5'-CTCTGGGTTGGCACACACTT-3'
<i>CXCL8</i> (IL-8)	Forward	5'-AAGAGAGCTCTGTCTGGACC-3'
	Reverse	5'-GATATTCTCTTGGCCCTTGG-3'
<i>CXCL10</i> (IP-10)	Forward	5'-TTCCTGCAAGCCAATTTTGTC-3'
	Reverse	5'-TCTTCTCACCTTCTTTTTTCATTGT-3'
<i>CXCL1</i>	Forward	5'-GCGCCCAAACCGAAGTCATA-3'
	Reverse	5'-ATGGGGGATGCAGGATTGAG-3'
<i>SeV</i>	Forward	5'-GACGCGAGTTATGTGTTTGC-3'
	Reverse	5'-TTCCACGCTCTCTTGGATCT-3'
<i>GAPDH</i>	Forward	5'-GCAAATTCCATGGCACCGT-3'
	Reverse	5'-TCGCCCCACTTGATTTTGG-3'

991